# OnCo record keynote-158 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-158/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-158", "NCT02628067" ;
  schema:name "KEYNOTE-158"@en ;
  schema:description "The basket trial that showed pembrolizumab alone rarely works in bile duct and gallbladder cancer: only 6 of 104 patients responded, though those who did stayed in response for years. It is also the trial behind the tumour-agnostic approvals of pembrolizumab for mismatch-repair-deficient and high mutation-burden cancers, which do apply to gallbladder cancer."@en ;
  schema:url <https://onco.cc/trials/keynote-158/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02628067>, <https://doi.org/10.1002/ijc.33013> ;
  onco:status "active" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tmb/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-158-j-clin-oncol-2019/>, <https://onco.cc/key-papers/paper-keynote-158-ann-oncol-2022-update/> .